July 9, 2014 | ASEAN, Asia, emerging markets
If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to consider in deciding which markets to research.
Home to over half a billion people, the 10 nations that make up the ASEAN region constitute the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an increasingly attractive and dynamic growth market for pharma manufacturers.
But with pharmaceutical market researchers being subjected to ever tighter budgets and timelines, conducting research in all ASEAN markets is rarely a viable option.
A common question amongst our clients interested in leveraging opportunities within the ASEAN markets is ‘if I can research only one ASEAN market for my product, how do I go about choosing one?’ A seemingly straightforward question, yet one which is actually quite difficult to answer.
Download and read the complimentary whitepaper at http://bit.ly/1IJ86oO
We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.Â
This content was provided by Inizio
Latest Content from Inizio
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?
Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.
This guidebook explores how Intelligent Congress helps pharma teams create more coordinated, measurable, and impactful congress strategies.
Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize…
Following ASCO® 2026, Inizio’s experts have shared their perspectives across three thought leadership articles, each exploring a different aspect of what this year’s congress revealed for pharmaceutical organisations. Together, they…
Key insights from ASCO® 2026, including oncology trends, scientific highlights, and strategies for smarter congress engagement.
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now…
Inizio, the global commercialization partner to the health and life sciences industry, today announced the launch of Intelligent Congress – a connected, end-to-end solution designed to help pharma organizations maximize…
Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence
Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercializationâ„¢. Now we’re back in the…
